Cipla reported INR9.55B in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
Arca Biopharma USD -25.07M 5.23M Mar/2025
aTyr Pharma USD 25.85M 52.43M Dec/2025
Bio Path USD -3.21M 631K Mar/2025
Brainstorm Cell Therapeutics USD -3.04M 99K Mar/2025
Capricor Therapeutics USD -27.23M 2.66M Jun/2025
Cara Therapeutics USD -2.39M 3.16M Mar/2025
Cipla INR 9.55B 3B Mar/2026
Dr.Reddys Laboratories INR 6.46B 14.43B Mar/2026
Esperion Therapeutics USD -9.93M 24.99M Sep/2025
Immunic USD -22.78M 753K Jun/2024
Infinity Pharmaceuticals USD -10.01M 1.39M Jun/2023
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Nektar Therapeutics USD -31.81M 70K Sep/2023
Sun Pharmaceuticals INR 39.54B 9.94B Mar/2026
TherapeuticsMD USD -1.64M 700K Sep/2023
UPL INR 35.58B 12.41B Mar/2026